Navigation Links
PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
Date:11/2/2009

ing proceeds from the securitization transaction to pay a special cash dividend to shareholders. The total and per share amount of the special dividend, together with the record and payment dates, will be decided by the Company's Board of Directors at its upcoming meeting on November 11, 2009 and will be announced the following day. The amount of the special dividend on a per share basis will be announced on the record date. PDL expects to pay the special dividend in 2009.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

The foregoing statements regarding PDL's intentions with respect to the cash dividend payment described above are forward-looking statements under the Private Securities Litigation Reform Act of 1995, and actual results could vary materially from the statements made. PDL's ability to complete the transactions and cash dividend payment described above successfully is subject to various risks, many of which are outside its control, including prevailing conditions in the capital markets and other risks and uncertainties as detailed from time to time in the reports filed by PDL with the Securities and Exchange Commission.

SOURCE PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly CEO Lechleiter Calls for Repair of the Engine of Biopharma Innovation
2. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
3. Helix BioPharma Corp. Announces Fiscal 2009 Results
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
9. PDL BioPharma Completes October 1 Special Dividend Payment
10. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
11. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
(Date:12/22/2014)... Calif. , Dec, 22, 2014  Eiger ... Phase 2a study of lonafarnib in patients with ... was conducted at the National Institutes of Health ... .  The double-blinded, randomized, placebo-controlled, dose ascending ... twice daily and 200 mg twice daily for ...
(Date:12/22/2014)... , Dec. 22, 2014  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, announced today ... dosed in a pharmacokinetic and pharmacodynamic study with ... neuropathic pain. Racemic methadone is a ... pain states and substitution therapy in opioid addiction.  ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... DATATRAK International, Inc. (OTCQX: DATA), a technology and ... clinical trials industry, today announced its attendance at the ... be held in Chicago, Illinois June 19th-23rd. ... #735 on June 20th-22nd. Individuals attending the meeting are ...
... SAN DIEGO, June 10, 2011 Gen-Probe Incorporated (NASDAQ: ... at the William Blair & Company 31st Annual Growth Stock ... p.m. Central Time (5 p.m. Eastern Time).  The presentation is ... a link on the investors section of Gen-Probe,s website at ...
Cached Medicine Technology:DATATRAK Exhibiting at 47th Annual DIA Meeting 2Gen-Probe to Webcast Presentation at the William Blair & Company 31st Annual Growth Stock Conference 2
(Date:12/24/2014)... (HealthDay News) -- Long-term fear of terrorists may damage your ... new study from Israel suggests. , , Conducted by researchers ... Israelis. In Israel, the threat of war and terrorism has ... "We wanted to test whether fear of terrorism can ... death," study author Hermona Soreq, a professor of molecular neuroscience, ...
(Date:12/24/2014)... 2014 (HealthDay News) -- If you are a high-risk ... are not treated by a cardiologist, new research suggests. ... cardiologists left town for annual professional meetings, Harvard researchers ... who were admitted to a teaching hospital during one ... percent died when these meetings were not taking place. ...
(Date:12/22/2014)... As early as thirty, gravity begins to ... form of “jowls." The dreaded droopiness usually appears around ... line or smile lines. Aging can be fought with ... the deep facial tissues descend, jowls inevitably appear. , ... can be used under the skin to fill natural ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic ... to their ad hoc report writing service to meet ... sign up for an annual subscription and get a ... a deeply discounted hourly rate. , Customers can ... progressively discounted rate. Subscription hours are contracted in 25 ...
(Date:12/22/2014)... York, New York (PRWEB) December 22, 2014 ... are a staple of the season. Many may be thinking ... in a span of a few weeks. Health Republic Insurance ... help of Registered Dietitian, Andrea Chernus, to provide some smart ... eat and stay healthy. , 1)    Avoid arriving at a holiday ...
Breaking Medicine News(10 mins):Health News:Terrorism Fears May Shorten Your Life, Study Finds 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 3Health News:Sam Rizk, MD, FACS, Introduces Rapid Recovery Facelift 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2
... of metabolic protein architecture and their advance offers ... ,,Researchers at the University of Illinois ... online edition of the Proceedings of the National Academy ... techniques of phylogenetic analysis developed in the past decade ...
... that it has a mix of properties that would ... matrix with metallic clusters that can absorb light, ... and then destroy those targeted cells with a laser. ... nanocomposite (DNC) matrix containing silver clusters that can be ...
... recently identified genetic marker for prostate cancer is linked ... ,These findings ultimately will aid the development ... susceptible to this aggressive cancer, Northwestern researchers said. Knowing ... doctors in how they treat the cancer. ...
... at Nokia have developed software that transforms a cellphone into ... lightning strike. ,A lightning bolt is an ... frequencies between 10 hertz and five gigahertz. However, the distribution ... is. ,According to the scientists, the multiple receivers ...
... toxic substance, made by certain types of bacteria found in house ... condition eczema or wheezing in children if they are exposed to ... Endotoxin is an element of the cell wall of gram-negative bacteria, ... when the bacteria dies or is damaged. ,The new ...
... The Most Powerful Weight-Loss Formula on Earth!" ... common in many parts of the world and thousands of ... is that there are few regulations to govern this booming ... ones that exist. ,Weight loss is a desperate ...
Cached Medicine News:Health News:Protein Folds Research Offers Insight into Metabolic Evolution 2Health News:Protein Folds Research Offers Insight into Metabolic Evolution 3Health News:Nanocomposite Labeled Cancer Cells Targeted and Destroyed by Using Lasers 2Health News:Genetic Marker Linked to Aggressive Prostate Cancer 2Health News:Beware Weight Loss Drugs, Say Canadian Experts 2Health News:Beware Weight Loss Drugs, Say Canadian Experts 3Health News:Beware Weight Loss Drugs, Say Canadian Experts 4
Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... in determining functionality of a patient's ... courses of treatment for patients receiving ... and autoimmune dieseases. Kit 030 ... diseases giving rise to high titers ...
Maximum brightness, durability, universal power suply, microprocessor-controlled light output and, in the event of lamp failure or degredation, automatic switchover to an integraged spare lamp....
Medicine Products: